Gut microbiota in early pediatric multiple sclerosis: a case−control study

European Journal of Neurology

Volumn 23, Issue 8, 2016, Pages 1308-1321

  Tremlett, H ^a   Fadrosh, D W ^b   Faruqi, A A ^b   Zhu, F ^a   Hart, J ^b   Roalstad, S ^c   Graves, J ^b   Lynch, S ^b   Waubant, E ^b   Aaen, Greg ^d   Belman, Anita ^d   Benson, Leslie ^d   Charles Casper, T ^d   Chitnis, Tanuja ^d   Gorman, Mark ^d   Harris, Yolanda ^d   Krupp, Lauren ^d   Lotze, Tim E ^d   Ness, Jayne ^d   Olsen, Cody ^d   Rodriguez, Moses ^d   Rose, John ^d   Simmons, Timothy C ^d   Tillema, Jan Mendelt ^d   Weinstock Guttman, Bianca ^d   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NONE

Author keywords

16S rRNA; case control study; gut microbiome; gut microbiota; immunomodulatory drugs; pediatric multiple sclerosis; risk factors

Indexed keywords

GLUTATHIONE; RNA 16S;

ADOLESCENT; ARTICLE; BILOPHILA; CHILD; CHRISTENSENELLACEAE; CLINICAL ARTICLE; CONTROLLED STUDY; DESULFOVIBRIO; DESULFOVIBRIONACEAE; FECES MICROFLORA; FEMALE; GLUTATHIONE METABOLISM; HUMAN; INTESTINE FLORA; LACHNOSPIRACEAE; MALE; METAGENOME; MICROBIAL COMMUNITY; MICROBIAL GENE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RNA SEQUENCE; RUMINOCOCCACEAE;

EID: 85027917252     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13026     Document Type: Article

References (41)

1. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun 2014; 38: 1–12.
2. Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett 2014; 588: 4207–4213.
3. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107–133.
4. Knight R. Follow Your Gut: The Enormous Impact of Tiny Microbes. Simon & Schuster: New York, NY, USA, 2015.
5. Siezen RJ, Kleerebezem M. The human gut microbiome: are we our enterotypes? Micro Biotech 2011; 4: 550–553.
6. Cantarel BL, Waubant E, Chehoud C, et al. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Invest Med 2015; 63: 729–734.
7. Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS One 2015; 10: e0137429.
8. Hunsberger M, O'Malley J, Block T, Norris JC. Relative validation of Block Kids Food Screener for dietary assessment in children and adolescents. Maternal Child Nutr 2015; 11: 260–270.
9. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME 2012; 6: 1621–1624.
10. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335–336.
11. Faruqi AA. Microbiome Analysis using Workflow of QIIME: GitHub, 2015 [cited 2015]. https://github.com/alifar76/MAWQ (accessed 06/2015)
12. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013; 31: 814–821.
13. Foxman B, Martin ET. Use of the microbiome in the practice of epidemiology: a primer on -omic technologies. Am J Epidemiol 2015; 182: 1–8.
14. R Core Team. R: A Language and Environment for Statistical Computing. 3.0.2. ed. Vienna, Austria: R Foundation for Statistical Computing; 2013.
15. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022–1023.
16. Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell 2014; 159: 789–799.
17. Segain J, de la Bletiere DR, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 2000; 47: 397–403.
18. Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol 2014; 52: 398–406.
19. International Multiple Sclerosis Genetics Consortium, Beecham AH, Patsopoulos NA, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353–1360.
20. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382–392.
21. Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis – current evidence and potential clinical applications. Aliment Pharmacol Ther 2014; 40: 409–421.
22. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731–16736.
23. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 968–984.
24. Jhangi S, Gandhi R, Glanz B, et al. Increased Archaea species and changes with therapy in gut microbiome of multiple sclerosis subjects (S24.001). Neurology 2014; 82: S24.001.AAN.
25. Baranzini SE, Katz-Sand I, Mazmanian SK, et al. The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS. Mult Scler 2014; 20: 285–496.
26. Mielcarz DW, Kasper LH. The gut microbiome in multiple sclerosis. Cur Treat Options Neurol 2015; 17: 344.
27. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 2015; 65: 57–62.
28. Vaahtovuo J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35: 1500–1505.
29. Surana NK, Kasper DL. The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunol Rev 2012; 245: 13–26.
30. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013; 155: 1451–1463.
31. Primary immunodeficiency - Homo sapiens (human) - Reference pathway [online]. KEGG. 2013 [December 15, 2014]. http://www.genome.jp/kegg-bin/show_pathway?hsa05340.
32. Glutathione metabolism – reference pathway: KEGG, 2014 [December 15, 2014]. http://www.genome.jp/kegg/pathway/map/map00480.html.
33. Lipopolysaccharide biosynthesis – reference pathway: KEGG, 2015 [December 15, 2014]. http://www.genome.jp/kegg-bin/show_pathway?map=map00540&show_description=show.
34. Carvalho AN, Lim JL, Nijland PG, Witte ME, Van Horssen J. Glutathione in multiple sclerosis: more than just an antioxidant? Mult Scler 2014; 20: 1425–1431.
35. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacolog Rev 2011; 63: 35–58.
36. Nogai A, Siffrin V, Bonhagen K, et al. Lipopolysaccharide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4+ cells. J Immunol 2005; 175: 959–966.
37. Benito-Leon J, Pisa D, Alonso R, Calleja P, Diaz-Sanchez M, Carrasco L. Association between multiple sclerosis and Candida species: evidence from a case−control study. Eur J Clin Microbiol Infect Dis 2010; 29: 1139–1145.
38. Hube B. From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr Opin Microbiol 2004; 7: 336–341.
39. Panzer AR, Lynch SV. Influence and effect of the human microbiome in allergy and asthma. Curr Opin Rheumatol 2015; 27: 373–380.
40. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2: e01202.
41. Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One 2013; 8: e76359.